TriangleNCT00509249 · REGISTRY CONDITION SEARCH
Aflibercept in Treating Patients With Myelodysplastic Syndromes
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE2
- Status at capture
- TERMINATED
- Registry last update
- 2015-01-08
This phase II trial is studying how well aflibercept works in treating patients with myelodysplastic syndromes. Aflibercept may be able to carry cancer-killing substances directly to myelodysplastic syndrome cells. It may also stop the growth of cancer cells by blocking blood flow to the cancer
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Patients must have histologically or cytologically confirmed myelodysplastic syndromes (MDS), including any of the following: * Secondary MDS * MDS/myeloproliferative disorders (MPD) (e.g., chronic myelomonocytic leukemia or atypical chronic myeloid leukemia) * IPSS scores of 0.5 or greater (≥ INT-1) OR transfusion dependent despite use of growth factors * No more than 20% blasts in the marrow * Patients who have not responded after 3 courses of hypomethylating agents (azacitidine or decitabine) OR; who are unable to tolerate hypomethylating agents OR who refused to receive hypomethylating agents are eligible for this study * ECOG performance status ≤ 2 (Karnofsky ≥ 60%) * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) * AST/ALT ≤ 2.5 x ULN * Creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 60 mL/min * Urine protein:creatinine ratio \< 1 OR urine protein \< 500 mg by 24-hour urine collection * PT INR ≤ 1.5 * Patients with PT INR \> 1.5 on full-dose anticoagulants (e.g., warfarin) are eligible provided both of the following criteria are met: * Patient has an in-range INR (usually between 2 and 3) and is on a stable dose of oral anticoagulant or low molecular weight heparin * Patient has no active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices) * Not pregnant or nursing * Fertile patients must use effective contraception during and for at least 6 months after completion of study treatment * Prior DNA-demethylating agent therapy or lenalidomide therapy allowed * Prior treatment with other molecular agents, such as thalidomide, valproic acid, or imatinib mesylate allowed Exclusion Criteria: * Evidence of active malignancies other than squamous cell or basal cell carcinoma of the skin * Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies * History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in the study * Serious or non-healing wound, ulcer, or bone fracture * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days * Significant traumatic injury within the past 28 days * Clinically significant cardiovascular disease, including any of the following: * History of cerebrovascular accident (CVA) within the past 6 months * Uncontrolled hypertension, defined as blood pressure \> 150/100 mm Hg or systolic BP \> 180 mm Hg if diastolic blood pressure \< 90 mm Hg (on at least 2 repeated determinations on separate days) within the past 3 months * Myocardial infarction or unstable angina within the past 6 months * New York Heart Association class III or IV congestive heart failure, serious cardiac arrhythmia requiring medication, or unstable angina pectoris within the past 6 months * Clinically significant peripheral vascular disease within the past 6 months * Pulmonary embolism, deep vein thrombosis (DVT), or other thromboembolic event within the past 6 months * Evidence of bleeding diathesis or coagulopathy * Concurrent uncontrolled illness including, but not limited to, ongoing or active infection or psychiatric illness/social situation that would limit compliance with study requirements * Prior cytotoxic chemotherapy for MDS * Molecular therapy or immunosuppressive agents (including steroids) within the past 3 weeks * Other prior antiangiogenesis agents * Coronary artery bypass graft (CABG) within the past 6 months * Valproic acid should be discontinued at least 24 hours before aflibercept administration, unless needed for seizure control * Major surgical procedure or open biopsy within the past 28 days * Core biopsy (other than bone marrow biopsy) within the past 7 days * Anticipation of need for major surgical procedures during the course of the study * Patients may not be receiving any other investigational agents
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Patients will receive aflibercept IV at 4 mg/kg over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
- intervention Names
- Biological: ziv-aflibercept
- Other: laboratory biomarker analysis
- Other: pharmacological study
- label
- Arm I
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Arm I
- description
- Given IV
- name
- ziv-aflibercept
- other Names
- aflibercept
- vascular endothelial growth factor trap
- VEGF Trap
- Zaltrap
- type
- BIOLOGICAL
- arm Group Labels
- Arm I
- description
- Correlative studies
- name
- laboratory biomarker analysis
- type
- OTHER
- arm Group Labels
- Arm I
- description
- Correlative studies
- name
- pharmacological study
- other Names
- pharmacological studies
- type
- OTHER
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 18
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Complete Response (CR): repeat bone marrow (BM) shows \<5% myeloblasts, and peripheral blood values lasting ≥ 2 months of hemoglobin (hgb) (\>110 g/L), neutrophils (≥1.0x10\^9/L), platelets (≥100x10\^9/L), blasts (0%) and no dysplasia. Partial Response (PR): same as CR for peripheral blood except BM shows blasts decrease by ≥ 50% but still \> 5% or a less advanced FAB classification from pretreatment. Hematological response=CR+PR.
- measure
- Hematological Response Rate
- time Frame
- Up to 3 years
Full study description
- brief Summary
- This phase II trial is studying how well aflibercept works in treating patients with myelodysplastic syndromes. Aflibercept may be able to carry cancer-killing substances directly to myelodysplastic syndrome cells. It may also stop the growth of cancer cells by blocking blood flow to the cancer
- detailed Description
- OBJECTIVES: I. To determine the antitumor activity of aflibercept as assessed by the hematological response rate. II. To determine overall and progression-free survival in patients with myelodysplastic syndromes. III. To assess hematologic improvement and time to leukemic transformation. IV. To assess the toxicity profile of aflibercept in this patient population. V. To perform correlative studies to better understand the ability of aflibercept to reach and modulate its respective targets. OUTLINE: This is a multicenter study. Patients will receive aflibercept IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Blood and bone marrow samples will be obtained periodically for pharmacokinetic and biomarker correlative studies. Pharmacokinetic analysis by ELISA; anti-aflibercept antibody measurements; analysis of VEGF and VEGFR expression; and analysis of gene expression by quantitative PCR will be conducted. The effect of aflibercept on apoptosis and proliferation of CD34+ cells will also be analyzed by flow cytometry based assays. After completion of study treatment, patients are followed periodically.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-b44f0ff9389cdb508b25
- requested nct id
- NCT00509249
- primary nct id
- NCT00509249
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
- payload sha256
- 473d163f9c5edea9122fa46397777728f14a27761bc22da4dcbd417a26cf1723
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-b44f0ff9389cdb508b25
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT00509249
- occurrences
- context exact
- NCT00509249
- end
- 11
- exact text
- NCT00509249
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Juvenile Myelomonocytic Leukemia
- query disease state id
- ds-juvenile-myelomonocytic-leukemia
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-juvenile-myelomonocytic-leukemia-000.json
- source file sha256
- cddcd4e3a59550bc78924062a298c359d8f811413f73f4a4461963aecf3790d6
- source json pointer
- /studies/110/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- a7d2f43fecaa540f41b50da6b7cf572bb33fb6b7691269d514e55949a815825c
Preserved source evidence · Not medical advice